课题基金 / 基金详情

Characterizing diacetylspermine as a biomarker of drug response and precision treatment in triple-negative breast cancer

Characterizing diacetylspermine as a biomarker of drug response and precision treatment in triple-negative breast cancer
将二乙酰精胺作为三阴性乳腺癌药物反应和精准治疗的生物标志物
批准号：
494927
负责人：
Velenosi Thomas J
金额：
$7.29万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
已结题
起止时间：
2023-09-01 至 2024-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=494927&lang=en
关键词：
Biomarkers Patient-Derived Xenograft Polyamines Triple Negative Breast Cancer

项目摘要

项目成果

Velenosi Thomas J的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Triple-negative breast cancer (TNBC) is the deadliest breast cancer subtype, in part due to lack of targeted therapy. Therefore, there is a need to improve methods that determine if treatment is effective and to develop targeted therapies. Cancer cells re
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing and validating diacetylspermine as a metabolic biomarker of drug response and precision treatment in triple-negative breast cancer
  • 批准号：
    472346
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2022
  • 负责人：
    Velenosi Thomas J
  • 依托单位：
    University of British Columbia
Metabolic signatures of triple negative breast cancer sensitivity and resistance to cyclophosphamide and doxorubicin in patient derived tumor xenografts
海外基金